These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36874124)

  • 1. The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis.
    Shen F; Li J; Liu F; Sun N; Qiu X; Ding W; Sun X
    Front Oncol; 2023; 13():1095362. PubMed ID: 36874124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anlotinib as Monotherapy or Combination Therapy for Recurrent High-Grade Glioma: A Retrospective Study.
    Yin J; Yin W; Zheng L; Li Y; Luo C; Zhang S; Duan L; Zhou H; Cheng K; Lang J; Xu K
    Clin Med Insights Oncol; 2023; 17():11795549231175714. PubMed ID: 37435019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma.
    She L; Su L; Shen L; Liu C
    Front Oncol; 2021; 11():687564. PubMed ID: 34354945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy plus temozolomide with or without anlotinib in H3K27M-mutant diffuse midline glioma: A retrospective cohort study.
    Liu C; Kuang S; Huang T; Wu J; Zhang L; Gong X
    CNS Neurosci Ther; 2024 Apr; 30(4):e14730. PubMed ID: 38644565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
    Zhong Q; Liu Z
    Cancer Manag Res; 2021; 13():4115-4128. PubMed ID: 34045898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficiency of Anlotinib in Patients with Recurrent Grade 4 Glioma: A Single-Center Retrospective Analysis.
    Wang Q; Wei W; Ji X; Li J; Wu N; Li J; Sun K; Ma C; Pan H
    Neurol India; 2024 May; 72(3):578-584. PubMed ID: 39041976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in
    He Z; Yang X; Ma T; Yang Q; Zhang C; Chen Y; Wang P; D'Incecco A; Metro G; Uematsu S; Wang Q
    Transl Lung Cancer Res; 2022 Aug; 11(8):1657-1666. PubMed ID: 36090635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis.
    Yang Q; Guo C; Lin X; Luo L; He Z; Lin F; Zhang J; Chen Y; Jiang X; Ke C; Mou Y
    Front Pharmacol; 2021; 12():804942. PubMed ID: 35002738
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of immune checkpoint inhibitors plus anlotinib in small cell lung cancer with brain metastases: a retrospective, multicentre study.
    Zhou S; Ren F; Li C; Jiang L; Meng X; Huang Z
    J Neurooncol; 2022 Dec; 160(3):631-642. PubMed ID: 36346496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study.
    Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Zhang R; Ruan ZP; Tian T; Liang X; Yao Y
    Cancer Manag Res; 2022; 14():2273-2287. PubMed ID: 35942069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective review of safety and efficacy of anlotinib in advanced osteosarcoma with metastases after failure of standard multimodal therapy.
    Li H; Li Y; Song L; Ai Q; Zhang S
    Asia Pac J Clin Oncol; 2023 Oct; 19(5):e314-e319. PubMed ID: 36658675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective study of anlotinib in patients with persistent, recurrent or metastatic cervical and endometrial cancer.
    Xin L; Ye M; Gao Y; Xiong Q; Hou Q
    Transl Cancer Res; 2024 Jul; 13(7):3718-3728. PubMed ID: 39145063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study.
    Liu Y; Ge Q; Xu S; Li K; Liu Y
    Front Oncol; 2022; 12():942678. PubMed ID: 36059654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
    Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
    Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial.
    Zhu J; Song C; Zheng Z; Xia L; Chen Y; Ke G; Wu X
    Front Oncol; 2021; 11():720343. PubMed ID: 34796105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.
    Liu J; Deng YT; Jiang Y
    Invest New Drugs; 2021 Apr; 39(2):330-336. PubMed ID: 32974853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in the Treatment of Patients with Advanced Primary Hepatocellular Carcinoma: A Retrospective, Real-World Study in China.
    Chen XQ; Zhao YX; Zhang CL; Wang XT; Zhang X; Chen X; Yuan CW; Zhao Q; Chen XJ
    Drug Des Devel Ther; 2022; 16():1483-1493. PubMed ID: 35607597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703).
    Chi Y; Shu Y; Ba Y; Bai Y; Qin B; Wang X; Xiong J; Xu N; Zhang H; Zhou J; Xu J; Cheng Y; Feng J; Hu C; Chen Y; Chen Z; Wang J; Dang C; Wang J; Wan Y; Tang Y; Wang D; Liu J; Wu M; Deng Y; Li X; Li Y; Dong J; Jiang D; Li G; Wu Q; Li J; Qi Y; Sun Y; Cai J
    Oncologist; 2021 Oct; 26(10):e1693-e1703. PubMed ID: 34105207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study.
    Nie C; He Y; Lv H; Gao M; Gao X; Chen B; Xu W; Wang J; Liu Y; Zhao J; Chen X
    Front Oncol; 2022; 12():885350. PubMed ID: 35860585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.